[Efficacy and safety of cefditoren pivoxil in treatment of respiratory infections, a clinical study].
OBJECTIVE
To evaluate the efficacy and safety of cefditoren pivoxil in treatment of respiratory infections.


METHODS
199 cases of respiratory infection confirmed by etiological and clinical examinations were treated with cefditoren pivoxil tablets taken orally. Therapeutic evaluation was conducted among 196 cases and safety evaluation was conducted among 199 cases.


RESULTS
The total effective rate was 94.9%, and the causative bacteria -elimination rate was 96.7%. Clinical adverse events, including moderate diarrhea, mild nausea and vomiting, and stomach discomfort, were seen in 9 cases with an incidence rate of 4.5%. Laboratory adverse events, including increase of with an incidence rate of 3.5%.


CONCLUSIONS
Cefditoren pivoxil is effective and safe in treatment of mild and moderate respiratory infections. The resistance rate to cefditoren pivoxil of pathogens of respiratory infections and the efficacy of cefditoren pivoxil show no difference from those tested 7 years ago.
Li
Jia-Tai
JT
Department of Antibiotics, Institute of Clinical Pharmacology, Peking University, Beijing 100083, China.
Gao
Lei
L
Xue
Feng
F
Hao
Feng-Lan
FL
Wang
Qi
Q
Cai
Bai-Qiang
BQ
Gan
Chun-Lan
CL
Liu
You-Ning
YN
Yu
Bing-Xiang
BX
He
Li-Xian
LX
Hu
Bi-Jie
BJ
Chen
Xue-Hua
XH
Zheng
Jing-Chuan
JC
Yu
Yun-Song
YS
Lu
Fang-Fang
FF
Liang
De-Rong
DR
Cai
Yong-Ning
YN
Kang
Jian
J
Kong
Ling-Fei
LF
Xiao
Zheng-Lun
ZL
Zheng
Jin-Ping
JP
Liu
Jie
J
Yang
Wei-Xing
WX
Zhou
Jing
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002511:Cephalosporins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D011358:Product Surveillance, Postmarketing; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000187:drug effects
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C057710:cefditoren pivoxil